Reports

The Worldwide Market for Laboratory-Developed Tests (LDTs), 2nd Edition provides a comprehensive analysis of the global sequencing market. This report covers market trends, challenges, strategies, and detailed profiles of key companies and products. It includes precise market share estimates and revenue growth forecasts, offering insights into the competitive landscape, including major deals and product developments.…

Urgent care centers (UCCs) are a vital and growing segment of the U.S. healthcare system, with around 10,000 locations nationwide. They offer walk-in care, a broad range of services, extended hours, and minimal wait times. Kalorama Information’s report, The U.S. Market for Urgent Care Centers (Including COVID-19, POC Tests, Vaccines and Other Sales), 2^nd Edition,…

We’ve Spoken To Your Customers

Understanding the overall customer experience, from pre-purchase experience, to product experience, to post-purchase experience, is more important now than ever before. Customer experience offers an opportunity for suppliers to differentiate themselves from other suppliers in a crowded life science marketplace on something more than product performance and price. An excellent…

For most manufacturing facilities in the food industry, laboratories must first test the raw materials that are purchased from an external supplier or farm. This must occur before they are allowed to be processed by the manufacturer. As the raw materials are processed, they are usually tested or monitored in some way. Samples tested during…

Environmental testing is a key area of the global analytical instrumentation market that looks at qualitatively and/or quantitatively analyzing contaminants in the environment. These contaminants can take many forms, from toxic chemicals in drinking water as the result of industrial processes to small particulate matter in the air we breathe. In order to protect from…

Customer experience in the clinical diagnostics industry is increasingly a target for improving overall customer satisfaction and a potential opportunity for differentiation beyond product performance, service plans, and price. This Kalorama Information report is an essential tool to learn how the in vitro diagnostics industry is seen from the point of view of their customers.

…

The SDi Global Assessment Report 2020: The Laboratory Analytical & Life Science Instrumentation Industry is the gold standard for market research reports in the analytical and life science instrument market.

Updated June 2020 to reflect the COVID-19 and related lab closure situation.

This report provides detailed data on every major life science and analytical instrument technology…

Companion diagnostics are revolutionizing pharmaceutical development and treatment, particularly in oncology. By identifying patients with specific biomarkers or disease-specific therapeutic targets, companion diagnostics significantly improve clinical success rates and patient outcomes. They also reduce costs by pinpointing the patient population most likely to benefit from a therapy and excluding those for whom the therapy would…

Outsourcing drug discovery represents the initial phase of the drug development process. By outsourcing segments of their drug discovery programs, pharmaceutical and biotechnology companies have discovered a cost-effective strategy that enhances hit-to-lead conversion and early identification of ineffective compounds. Outsourcing accelerates the drug discovery process, transforming the industry from low-end research services to high-value, sophisticated…

The global demand for biopharmaceuticals is expanding at a rapid pace, as they are more extensively accepted for the clinical treatment of a wide range of ailments. Unlike small molecule drugs, these biomolecule-based therapeutics, or biologics, are produced using living cells in two distinct phases, called upstream and downstream, which necessitates unique manufacturing processes collectively…

Contract research organizations (CROs) are essential partners in the drug development field. As companies in the pharmaceutical and biotechnology industries shift their development pipelines towards more targeted therapies, the cost of development has significantly increased while the patient pool for each drug is smaller. This has resulted in leaner R&D infrastructures and increasing reliance on…